基本信息
views: 0
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Mohamed Sallam, since 2022 till present, has been a PhD HDR at Griffith University (ESC, QMNC, and GRIDD), working on developing a self-assembled multimodal hybrid biopolymer for targeted radionuclide theranostics. M. Sallam, since 2018 till present, is a start-up mentor at imec.istart company, a subsidiary technology business-interface entity of IMEC (the world-leading R&D and innovation hub in nano-electronics and digital technologies). The main role of ‘imec.istart mentorship’ is to unite a group of leading industry and business professionals eager to share their experienced insights and advice with one or more mentees.
M. Sallam was, from 2013 to 2018, a scientific researcher at Vlaams Interuniversitair instituut voor Biotechnologie VIB in collaboration with Janssen Pharmaceutica, Johnson and Johnson, responsible for structural characterisation of the intrinsically disordered region of the human androgen receptor and its splice variants for drug development against castration-resistant prostate cancer. The research collaboration utilised a wide range of state-of-the-art biophysical and biochemical techniques for small molecules, high-throughput screening, protein-protein interaction, and complex formation inhibitors. In 2013, M. Sallam was a scientific researcher at the German Cancer Research Center – DKFZ and the Nationales Centrum für Tumorerkrankungen - NCT Heidelberg, responsible for developing novel bi-specific CAR designs for breast cancer T cell immunotherapy. The research work was in collaboration with Bayer Pharma, Germany, where genetically modified T cells could be alternatively generated using novel transposon systems to stably introduce CARs in T lymphocytes.
Previously, from 2010 to 2013, M. Sallam was a teacher and Researcher Assistant at American University in Cairo (AUC) in collaboration with Vrije Universiteit Brussel (VUB), Belgium, responsible for managing and executing a collaboration project for developing new diagnostic and therapeutic green-chemistry techniques for various diseases, particularly breast cancer and a range of other parasitic diseases (e.g., Malaria, Trypanosomiasis, Bilharziasis and Filariasis). The project was mainly about developing mAbs and single-domain antibodies – Nanobodies - VHH against target-specific antigens and bioconjugation with metallic nanoparticles and graphene-coated magnetic nanoparticles for theranostic applications.
From 2005 to 2010, he was the Technical Development Manager at Egyptian Mud Engineering & Chemicals Company (EMEC), responsible for market research and market development about the most recent technologies in the field of fluids engineering. Together with multiple teams (programmers, mathematicians, numerical analysts, data scientists, graphic designers, and database administrators), they developed a state-of-the-art downhole drilling simulator. Afterwards, M. Sallam provided technical support services for field operations engineers 24 hours a day, 7 days a week, to maintain rapid response to operational problems. In addition, he prepared training materials for staff members, including brochures, technical notes, and an operation manual. Then he trained and coached all the company’s staff members (3600 engineers within 13 countries in the MENA, GCC, and East Europe regions), including managers, district managers, area supervisors, and fluids engineers. From 2002 to 2005, he was a Drilling Fluids Operations Specialist in Syria, Iraq, and Libya at EMEC, Performing and troubleshooting all technical issues in field operations.
From 1999 to 2002, M. Sallam was a Research Assistant in immunology and genetic Engineering at the Research & Training Center on Vector of Disease (RTC), Ain Shams University, Cairo, Egypt in collaboration with Washington State University and the Barnes Jewish Hospital St Louis. During the same period, he was the genetic engineering technical representative and sales manager for the FISH technique (molecular labelled probes, Vysis Inc., USA, and fluorescent microscopes from Olympus, Germany) for early detection of protooncogenes of various types of cancer, in Egypt, England, and Germany.
Research Interests
Papers共 9 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Mohamed Sallam,Kimberley Clack,Ema Romão, Cong Minh Nguyen, Amandeep Singh Pannu, Tanzena Tanny, Frank Sainsbury,Nam-Trung Nguyen,Pieter De Pauw,Nick Devoogdt,Nobuo Kimizuka,Serge Muyldermans
crossref(2024)
Rabbee G. Mahmudunnabi,Surasak Kasetsirikul,Narshone Soda,Mohamed Sallam, Amandeep Singh Pannu, Nam-Trung Nguyen,Helen Stratton,Muhammad J. A. Shiddiky
Mohamed Sallam, Nam-Trung Nguyen, Frank Sainsbury, Nobuo Kimizuka,Serge Muyldermans, Martina Benešová-Schäfer
Theranosticsno. 8 (2024): 3043-3079
crossref(2024)
Kimberley Clack,Mohamed Sallam,Serge Muyldermans,Prabhakaran Sambasivam, Cong Minh Nguyen,Nam-Trung Nguyen
MICROMACHINESno. 2 (2024): 216
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRYno. 31 (2023): 11765-11788
MICROMACHINESno. 11 (2023): 2101-2101
ACS sensorsno. 7 (2023): 2493-2513
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn